FDA’s accelerated approval program: Is change on the way?
Regulatory NewsMary Ellen Schneider
BiologicsFDA meeting and communication strategyNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyRegulatory NewsMary Ellen SchneiderBiologicsFDA meeting and communication strategyNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy